SecBot SecBot
EFFECT ·Filed Jul 22, 2026

OTLK

Outlook Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC9999999995-26-002376
IPO/offering going effective
Actionable Insight • Neutral

The effectiveness gives Outlook Therapeutics flexibility to raise capital opportunistically. Monitor for any prospectus supplement in the coming weeks that would indicate an actual offering. Given the company's pre-revenue status, the shelf signals readiness for a potential capital raise.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.34
T+0 close · Jul 22, 2026 · via day close
Latest settled
−62.69%
T+60 · $0.5000
Vs SPY
−65.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $1.34entry
  2. T+1 · 4mo ago −1.49%α −0.26% · $1.32
  3. T+5 · 4mo ago −25.37%α −22.97% · $1.00
  4. T+20 · 3mo ago −48.50%α −51.40% · $0.6901
  5. T+60 · 5w ago −62.69%α −65.95% · $0.5000
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The SEC declared effective Outlook Therapeutics' S-3 shelf registration statement on July 21, 2026. This allows the company to offer and sell securities from time to time without additional SEC review, creating potential dilution overhang but no immediate capital raise. As a pre-revenue biotech, the shelf provides flexibility for future financing.

Key Facts

  • S-3 shelf registration declared effective on July 21, 2026
  • Company can now offer securities at any time without additional SEC review
  • No specific offering amount or pricing disclosed in the effectiveness notice

Financial Impact

Potential future dilution from shelf takedowns; no immediate financial impact.

dilutioncapital raising

Risk Factors

  • Future dilution from share issuance under the shelf
  • No revenue base to offset dilutive effects of any offering

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002376
Document: 9999999995-26-002376-index.html9999999995-26-002376
Document: 9999999995-26-002376.txt9999999995-26-002376

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026